Research programme: antibacterials - BioWest

Drug Profile

Research programme: antibacterials - BioWest

Alternative Names: MBI 2046; MBI 2401; MBI-1396; MX 2401

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ardea Biosciences; BioSource Pharm
  • Developer Carrus Capital Corporation
  • Class Antibacterials; Lipoproteins; Peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Gram-positive infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-positive-infections in Canada (IV)
  • 19 Aug 2011 BioWest Therapeutics is now called Carrus Capital Corporation
  • 15 Sep 2009 Pharmacodynamics data from a preclinical trial in Gram-positive infections presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top